| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/03/2010 | CA2744323A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 06/03/2010 | CA2744055A1 Polypeptides, antibody variable domains & antagonists |
| 06/03/2010 | CA2744054A1 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 06/03/2010 | CA2744043A1 Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
| 06/03/2010 | CA2742791A1 Stable antibody compositions and methods for stabilizing same |
| 06/03/2010 | CA2742295A1 Improved methods for isolating enveloped virus-based vlps free of infectious agents |
| 06/03/2010 | CA2741724A1 Promoters for recombinant viral expression |
| 06/03/2010 | CA2740900A1 Antibodies that specifically block the biological activity of a tumor antigen |
| 06/03/2010 | CA2740566A1 Peptide adjuvants |
| 06/02/2010 | EP2192188A1 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| 06/02/2010 | EP2192173A1 Immortalized avian cell lines for virus production |
| 06/02/2010 | EP2192131A1 Immunoglobulins devoid of light chains |
| 06/02/2010 | EP2192130A1 Human DR4 antibodies and uses thereof |
| 06/02/2010 | EP2192128A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/02/2010 | EP2192127A1 Haemophilus influenzae type IV Pili |
| 06/02/2010 | EP2191849A1 Drug for suppressing pathogen occurring<i>in vivo</i> |
| 06/02/2010 | EP2191846A1 Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same |
| 06/02/2010 | EP2191845A1 Immunology significant herpes simplex virus antigens and methods for using same |
| 06/02/2010 | EP2191844A1 Injectable vaccines against multiple meningococcal serogroups |
| 06/02/2010 | EP2191843A1 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| 06/02/2010 | EP2191842A1 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| 06/02/2010 | EP2191841A1 Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| 06/02/2010 | EP2191840A1 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| 06/02/2010 | EP2191839A2 Immunogenic LHRH compositions and methods relating thereto |
| 06/02/2010 | EP2191836A1 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
| 06/02/2010 | EP2191273A1 Upregulation of rack-1 in melanoma and its use as a marker |
| 06/02/2010 | EP2190974A1 Apparatus and method for dehydrating biological materials |
| 06/02/2010 | EP2190881A1 Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| 06/02/2010 | EP2190880A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 06/02/2010 | EP2190879A1 Novel antibodies |
| 06/02/2010 | EP2190878A1 Novel methods and antibodies for treating cancer |
| 06/02/2010 | EP2190876A1 Antibodies against human cytomegalovirus (hcmv) |
| 06/02/2010 | EP2190875A1 Immunoglobulins directed to bacterial viral and endogenous polypeptides |
| 06/02/2010 | EP2190870A1 Cell marker of melanocyte cell lineage and uses thereof |
| 06/02/2010 | EP2190865A1 Hypoallergenic molecules |
| 06/02/2010 | EP2190861A2 Activatable binding polypeptides and methods of identification and use thereof |
| 06/02/2010 | EP2190479A1 Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions |
| 06/02/2010 | EP2190478A1 Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| 06/02/2010 | EP2190477A1 Donor specific antibody libraries |
| 06/02/2010 | EP2190476A1 Formulations of antibodies and fc-fusion molecules using polycations |
| 06/02/2010 | EP2190475A1 Methods of enhancing adjuvanticity of vaccine compositions |
| 06/02/2010 | EP2190473A2 Peptide with reduced dimer formation |
| 06/02/2010 | EP2190470A1 Vaccines |
| 06/02/2010 | EP2190469A2 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
| 06/02/2010 | EP2190468A2 Methods and compositions for modulating t cells |
| 06/02/2010 | EP1949913B1 Immunostimulatory combination for the prophylactics and treatment of hepatitis c |
| 06/02/2010 | EP1830881B1 Combining therapies targeting multiple toll-like receptors and use thereof |
| 06/02/2010 | EP1768697B1 Recombinant rabies virus compositions |
| 06/02/2010 | EP1697521B1 Multi plasmid system for the production of influenza virus |
| 06/02/2010 | EP1534736B1 Nogo receptor antagonists |
| 06/02/2010 | EP1438299B1 Bifunctional chelating agent for actinium |
| 06/02/2010 | CN1291231B Human telomerase catalytic subunit |
| 06/02/2010 | CN101720436A Methods and agents for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells |
| 06/02/2010 | CN101720232A fc receptor-binding polypeptides with modified effector functions |
| 06/02/2010 | CN101720231A Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| 06/02/2010 | CN101720230A Pharmaceutical composition comprising the anti-4-1bb antibody for treating or preventing rheumatoid arthritis |
| 06/02/2010 | CN101720229A Combinations of gene deletions for live attenuated shigella vaccine strains |
| 06/02/2010 | CN101720228A Live bacterial vaccines for viral infection prophylaxis or treatment |
| 06/02/2010 | CN101720227A Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| 06/02/2010 | CN101717779A Fusion protein suitable for anthrax antitoxin and vaccines |
| 06/02/2010 | CN101717775A Single-chain antibody gene of anti-human death receptor 5 |
| 06/02/2010 | CN101717754A Enterovirus type 71 and use thereof |
| 06/02/2010 | CN101717433A Polypeptide immunogen, preparation method and application thereof |
| 06/02/2010 | CN101716350A AIDS live carrier multipartial vaccine and construction method thereof |
| 06/02/2010 | CN101716343A Freeze-drying preparation of monoclonal antibody |
| 06/02/2010 | CN101716342A New castle disease and infectious bronchitis integrated inactivated vaccine and manufacture method thereof |
| 06/02/2010 | CN101716341A Human diploid cell inactivated rabies vaccine and preparation method thereof |
| 06/02/2010 | CN101716340A Establishment of method for preparing recombinant protein vaccine of type A H1N1 influenza virus |
| 06/02/2010 | CN101716339A IL-12 and TNF-alpha autologous tumor vaccine |
| 06/02/2010 | CN101716338A DNA vaccine for promoting regeneration and functional rehabilitation of nerves of central system |
| 06/02/2010 | CN101195823B Novel bacterium surface exhibiting system, method and application of the same |
| 06/01/2010 | US7728121 Nucleotide sequences coding portion of viral early gene; generating immunoglobulin for detecting viral infection |
| 06/01/2010 | US7728111 Anti-p55 TNF receptor antibody |
| 06/01/2010 | US7728109 Antagonistic anti-hTNFSF13b human antibodies |
| 06/01/2010 | US7727957 Treatment and delay of outset of Parkinson's disease |
| 06/01/2010 | US7727956 Deoxonadepsipeptides |
| 06/01/2010 | US7727954 alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of therapeutic agents to inhibit inflammatory response which causes pain; controlled and directed delivery provided by drug depot implants, comprising therapeutic agent delivered to desired location |
| 06/01/2010 | US7727757 For invoking an immune response, delaying the onset of AIDS in an animal exposed to infectious HIV |
| 06/01/2010 | US7727735 Detection and treatment of prostate cancer |
| 06/01/2010 | US7727711 Using type IV secretion (T4S) substrate (BepA) specific immunoglobulin to diagnose proteobacterium infection |
| 06/01/2010 | US7727550 Biologically active native biomatrix composition |
| 06/01/2010 | US7727543 Biodegradable carrier and method for preparation thereof |
| 06/01/2010 | US7727538 Methods and compounds for the treatment of mucus hypersecretion |
| 06/01/2010 | US7727537 Stabilized compositions for topical administration and methods of making same |
| 06/01/2010 | US7727536 EG-VEGF nucleic acids and polypeptides and methods of use |
| 06/01/2010 | US7727535 Protein comprising amino acid sequence with one to 20 amino acid substitutions, deletions or insertions; lower affinity binding to alpha thrombin, lower aggregation, or proteolysis resistance; inflammation, thrombosis, atherosclerosis, angioplasty-related restenosis; cardiovascular disorders |
| 06/01/2010 | US7727534 Gentically engineered viral particles for use in targeted tumor destruction; Antitumor agents |
| 06/01/2010 | US7727533 Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 06/01/2010 | US7727532 G-protein specific immunoglobulin targeting and treatment of viral disorders; Drug screening |
| 06/01/2010 | US7727531 Antibodies for preventing and treating attaching and effacing Escherichia coli (AEEC) associated diseases |
| 06/01/2010 | US7727530 Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody |
| 06/01/2010 | US7727529 Hepatitis c viral E2 glycoprotein specific immunoglobulin for use in prevention and treatment of hepatitis infection |
| 06/01/2010 | US7727528 Tumor necrosis factor receptor 1 specific immunoglobulins for targeted immaging and treatment and diagnosis of cell proliferative and autoimmune disorders |
| 06/01/2010 | US7727527 Anti-NGF antibodies for the therapeutic treatments |
| 06/01/2010 | US7727526 Use of PTHrP antagonists for treating renal cell carcinoma |
| 06/01/2010 | US7727525 Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics |
| 06/01/2010 | US7727523 Graft versus host disease, induce monocytes in the blood to differentiate into dendritic cells, incubation the mixture of dendritic cells from transplant donor and recipient, administering the co-incubated dendritic cells to recipients |
| 06/01/2010 | US7727518 Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B |
| 06/01/2010 | CA2512040C Designed deimmunized monoclonal antibodies for protection against hiv exposure and treatment of hiv infection |
| 06/01/2010 | CA2441952C Plasmodium falciparum ama-1 protein and uses thereof |